TYRO3 and cancer: A pathway that is implicated in dormancy maintenance across multiple cancer types in bone is GAS6 expressed by osteoblast lineage cells and also breast cancer cells [39], binding to TYRO3, AXL or MER (TAM) tyrosine kinase receptors, although the type of receptor expressed varies across cancer types.